Stock T5O BIOXXMED AG
Add to a list
To use this feature you must be a member
Log inSign up

Financials bioXXmed AG

Equities

T5O

DE000A0KFRJ1

Biotechnology & Medical Research

Market Closed - Xetra
Other stock markets
 11:36:08 2024-04-26 am EDT 		5-day change 1st Jan Change
0.488 EUR +4.27% Intraday chart for bioXXmed AG +3.83% +9.42%
2023 BioXXmed AG Reports Earnings Results for the Half Year Ended June 30, 2023 CI
2023 BioXXmed AG Reports Earnings Results for the Full Year Ended December 31, 2022 CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 22.42 14.67 37.19 65.66 19.01 5.908
Enterprise Value (EV) 1 20.46 11.98 35.18 64.09 19.13 4.068
P/E ratio -21.4 x - -30 x -35.7 x -4.68 x -7.12 x
Yield - - - - - -
Capitalization / Revenue 250 x 14,513 x 1,028 x 1,824 x 426 x 483 x
EV / Revenue 228 x 11,853 x 972 x 1,780 x 429 x 333 x
EV / EBITDA -20.8 x -10 x -30.4 x -35.7 x -12.4 x -4.97 x
EV / FCF 17.2 x 1,179 x -10.1 x -68.5 x - -6.08 x
FCF Yield 5.8% 0.08% -9.86% -1.46% - -16.5%
Price to Book 2.16 x - 2.15 x 2.99 x 1.06 x 0.28 x
Nbr of stocks (in thousands) 2,086 2,120 3,397 4,028 4,028 5,137
Reference price 2 10.75 6.920 10.95 16.30 4.720 1.150
Announcement Date 5/9/18 6/13/20 6/13/20 7/1/21 6/30/22 6/23/23
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 0.0898 0.001011 0.0362 0.036 0.0446 0.0122
EBITDA 1 -0.9816 -1.194 -1.156 -1.796 -1.548 -0.8177
EBIT 1 -1.018 -1.224 -1.175 -1.817 -1.569 -0.823
Operating Margin -1,132.89% -121,019.39% -3,248.16% -5,048.29% -3,516.49% -6,727.67%
Earnings before Tax (EBT) 1 -1.065 -1.422 -1.275 -1.839 -4.059 -0.8298
Net income 1 -1.065 -1.422 -1.275 -1.839 -4.059 -0.8298
Net margin -1,185.93% -140,611.77% -3,523.77% -5,108.88% -9,095.43% -6,783.59%
EPS 2 -0.5024 - -0.3652 -0.4566 -1.008 -0.1615
Free Cash Flow 1 1.187 0.0102 -3.468 -0.9353 - -0.6695
FCF margin 1,321.41% 1,005.54% -9,584.12% -2,597.95% - -5,472.6%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 5/9/18 6/13/20 6/13/20 7/1/21 6/30/22 6/23/23
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - 0.12 -
Net Cash position 1 1.96 2.69 2.01 1.57 - 1.84
Leverage (Debt/EBITDA) - - - - -0.0783 x -
Free Cash Flow 1 1.19 0.01 -3.47 -0.94 - -0.67
ROE (net income / shareholders' equity) -10.4% -11.8% -8.16% -9.27% -20.4% -4.22%
ROA (Net income/ Total Assets) -5.62% -5.3% -4.29% -5.66% -4.84% -2.58%
Assets 1 18.95 26.84 29.71 32.51 83.93 32.17
Book Value Per Share 2 4.970 - 5.080 5.440 4.440 4.170
Cash Flow per Share 2 0.9700 - 0.5800 0.3900 0 0.3600
Capex 1 0 0.01 0.01 0 - 0
Capex / Sales 4.45% 989.12% 38.69% 8.33% - 29.45%
Announcement Date 5/9/18 6/13/20 6/13/20 7/1/21 6/30/22 6/23/23
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BIOXXMED AG Stock bioXXmed AG
+9.42% 2.68M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. T5O Stock
  4. Financials bioXXmed AG